Abstract
Amyloid β-derived diffusible ligands (ADDLs) comprise the neurotoxic subset of soluble Aβ1-42 oligomers, now widely considered to be the molecular cause of memory malfunction and neurodegeneration in Alzheimers disease (AD). We have developed a screening cascade which identifies small molecule modulators of ADDL-mediated neurotoxicity. The primary screen involves a fluorescence resonance energy transfer (FRET)-based assay which selects inhibitors of Aβ1-42 oligomer assembly. The identified hits were further characterized by assessing their ability to inhibit the assembly and binding of ADDLs to cultures of primary hippocampal neurons. This approach has led to the identification of a number of small molecules which inhibit ADDL assembly and their subsequent binding to neurons. Here we describe our small molecule discovery efforts to identify ADDL assembly blocker and ADDL binding inhibitors, and to transform validated hits into pre-clinical lead compounds.
Keywords: ADDL, Alzheimer, amyloid, assembly, drug, inhibitor, neuron, oligomer
Current Alzheimer Research
Title: Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease
Volume: 4 Issue: 5
Author(s): Raymond M. Lowe, Grant A. Krafft, David Summa, William F. Goure, Susan M. Catalano, Sue Zhang, Hsiu-Mei Wu, Lily Ruslim-Litrus, Michele McEntee, Gary C. Look, Catherine M. Hironaka, Lev Igoudin, Walter J. Crosier, Jean-Claude R. Breach, Todd R. Pray, Diana B. Cherbavaz and Jasna Jerecic
Affiliation:
Keywords: ADDL, Alzheimer, amyloid, assembly, drug, inhibitor, neuron, oligomer
Abstract: Amyloid β-derived diffusible ligands (ADDLs) comprise the neurotoxic subset of soluble Aβ1-42 oligomers, now widely considered to be the molecular cause of memory malfunction and neurodegeneration in Alzheimers disease (AD). We have developed a screening cascade which identifies small molecule modulators of ADDL-mediated neurotoxicity. The primary screen involves a fluorescence resonance energy transfer (FRET)-based assay which selects inhibitors of Aβ1-42 oligomer assembly. The identified hits were further characterized by assessing their ability to inhibit the assembly and binding of ADDLs to cultures of primary hippocampal neurons. This approach has led to the identification of a number of small molecules which inhibit ADDL assembly and their subsequent binding to neurons. Here we describe our small molecule discovery efforts to identify ADDL assembly blocker and ADDL binding inhibitors, and to transform validated hits into pre-clinical lead compounds.
Export Options
About this article
Cite this article as:
Lowe M. Raymond, Krafft A. Grant, Summa David, Goure F. William, Catalano M. Susan, Zhang Sue, Wu Hsiu-Mei, Ruslim-Litrus Lily, McEntee Michele, Look C. Gary, Hironaka M. Catherine, Igoudin Lev, Crosier J. Walter, Breach R. Jean-Claude, Pray R. Todd, Cherbavaz B. Diana and Jerecic Jasna, Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018271
DOI https://dx.doi.org/10.2174/156720507783018271 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia
Current Neuropharmacology NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Current Neuropharmacology An Observational Study of the Needs and Quality of Life Amongst Patients in the Treatment of Alzheimers Dementia with Cholinesterase Inhibitors
Current Aging Science Rivastigmine Transdermal Patch and Physical Exercises for Alzheimer's Disease: A Randomized Clinical Trial
Current Alzheimer Research Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Interaction Between HIV-1 and APOBEC3 Sub-Family of Proteins
Current HIV Research Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice
CNS & Neurological Disorders - Drug Targets Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds
Current Medicinal Chemistry Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD
Current Alzheimer Research Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Current Drug Targets